FENC

Fennec Pharmaceuticals Inc. (FENC) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the commercialization of PEDMARK (sodium thiosulfate injection), the first and only FDA-approved therapy to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also holds an exclusive license with Norgine to commercialize the product (branded as PEDMARQSI) in Europe, the UK, Australia, and New Zealand.

Key Financial Metrics

Profitability & Margins: The company achieved net income for the first time in the reported periods, driven by significant revenue growth and reduced interest expenses. Gross margin on product sales was approximately 96% ($15,108 revenue vs. $570 cost of sales). Operating margin improved significantly from a loss of 9.2% of revenue in Q1 2025 to a near-breakeven loss of 0.8% in Q1 2026.

Liquidity & Debt: As of March 31, 2026, the company held $40.2 million in cash. There is no long-term debt reported on the balance sheet; the company repaid its Petrichor convertible notes in Q4 2025. Total liabilities were $34.1 million, primarily consisting of long-term contract liabilities ($24.6 million) related to the Norgine license agreement.

Material Changes vs. Prior Period

• Revenue Growth: Net product sales increased by 73% ($6.4 million) year-over-year, driven by increased market penetration and access programs for PEDMARK in the U.S.
• Operating Expenses:
  • Selling and Marketing: Increased by 254% ($8.2 million) to $11.4 million due to a higher commercial headcount and expanded sales organization to support U.S. market coverage.
  • General and Administrative (G&A): Decreased by 46% ($2.7 million) to $3.2 million, primarily due to lower legal and professional fees as litigation activities concluded.
  • Research and Development: Decreased by $45,000 to $49,000, reflecting a focus on investigator-initiated trials rather than large-scale development.
• Interest Expense: Decreased by $585,000 to $7,000 following the full repayment of convertible notes in late 2025, eliminating related interest and accretion costs.
• Cash Flow: Operating cash flow swung from a use of $4.3 million in Q1 2025 to a generation of $2.4 million in Q1 2026, driven by the shift to net income and favorable working capital movements (specifically a $4.5 million decrease in accounts receivable).

Guidance, Outlook, and Risks

Management Commentary & Outlook: Management believes existing cash and expected revenues are sufficient to fund operations for at least the next 12 months. The company is pursuing strategic alternatives, including collaborations. In Japan, positive topline results from an investigator-initiated trial (STS-J01) announced in December 2025 are driving a regulatory registration strategy and potential licensing discussions.

Key Developments:

• Cipla Litigation Settlement: On March 16, 2026, Fennec announced a settlement with Cipla Ltd. resolving patent infringement litigation. Under the agreement, Cipla will not enter the U.S. market with a generic sodium thiosulfate product until September 1, 2033, extending market exclusivity visibility.
• International Expansion: Norgine launched PEDMARQSI in Germany and the UK in 2025, with additional launches planned for 2026.

Risks & Contingencies:

• Patent Litigation: While the Cipla case is settled, the company notes risks regarding potential future patent claims from third parties.
• Concentration Risk: Four distributors represented more than 10% of net sales in Q1 2026.
• Regulatory & Market Access: Revenue recognition relies on estimates for rebates, chargebacks, and discounts, which could vary from actuals.

Investor Verification Checklist

• Verify the September 1, 2033 generic entry date for Cipla as stated in the settlement agreement to confirm the extended exclusivity profile.
• Monitor the working capital cycle, specifically the sustainability of the $4.5 million reduction in accounts receivable observed in Q1 2026.
• Review the Norgine license agreement milestones to understand the timing and probability of the potential $230 million in future milestone payments.
• Assess the burn rate relative to the $40.2 million cash balance, noting the significant increase in Selling and Marketing expenses ($11.4M) as the company scales its U.S. commercial team.
• Confirm the status of the Japan regulatory strategy following the positive STS-J01 trial results.